Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 463,100 shares, a growth of 483.2% from the January 31st total of 79,400 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 8.0% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Saturday, February 22nd. They set a “sell” rating for the company.

Bio-Path Stock Performance

NASDAQ BPTH traded down $0.01 on Friday, hitting $0.18. 72,645 shares of the stock were exchanged, compared to its average volume of 1,608,272. Bio-Path has a 52 week low of $0.12 and a 52 week high of $7.67. The business’s fifty day moving average is $0.79 and its 200 day moving average is $0.91.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.